SCHEMBL16886158

SCHEMBL16886158

Cc1ccc(COc2cc(F)cc(Oc3ccc(-c4nn(CCN5CCCC5)c5ncnc(N)c45)cc3)c2)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 7/20 0.51
▸ YES1 P07947 5/20 0.51
▸ FGR P09769 5/20 0.51
▸ FYN P06241 4/20 0.48
▸ LYN P07948 2/20 0.48
▸ ABL1 P00519 3/20 0.47
▸ LCK P06239 2/20 0.47
▸ RET P07949 1/20 0.47
▸ FRK P42685 1/20 0.47
▸ BTK Q06187 6/20 0.45
▸ FGFR2 P21802 4/20 0.43
▸ FGFR1 P11362 4/20 0.43
▸ FGFR3 P22607 3/20 0.43
▸ FGFR4 P22455 3/20 0.43
▸ PIK3C2B O00750 1/20 0.42
▸ NUDT14 O95848 1/20 0.42
▸ NUDT5 Q9UKK9 1/20 0.42
▸ EGFR P00533 1/20 0.41
▸ JAK3 P52333 1/20 0.41
▸ ITK Q08881 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16886171 0.95 SRC (0.50) SRCYES1FGRFYNLYN
SCHEMBL16886163 0.91 SRC (0.46) SRCYES1FGRFYNLYN
SCHEMBL15613665 0.91 SRC (0.49) SRCYES1FGRFYNLYN
SCHEMBL16886182 0.89 SRC (0.49) SRCYES1FGRFYNLYN
SCHEMBL16886166 0.86 NUDT14 (0.57) SRCABL1BTKNUDT14NUDT5
SCHEMBL15613670 0.86 SRC (0.49) SRCYES1FGRFYNLYN
SCHEMBL16886189 0.85 MAPK1 (0.47) SRCYES1FGRFYNLYN
SCHEMBL16886202 0.84 KCNH2 (0.55) SRCYES1FGRFYNLYN
SCHEMBL16886156 0.83 BTK (0.60) SRCLYNABL1LCKBTK
SCHEMBL15613649 0.83 SRC (0.45) SRCYES1FGRFYNLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK SRC 2/4885YES1 39/4885FGR 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback